Design, Structure-Activity, Labelling and Purity in the Development of Receptor Interacting Radiohalogenated Tracers
The design and development of new radiohalogenated tracers for in vivo measurement of brain receptor related processes is due, to its complexity, the work of pharmaceutical companies or large multidisciplinary research groups. For the development of radiopharmaceuticals generally a compound is chosen based on its known pharmacological properties and a strategy must be developed to introduce the radioisotope.
KeywordsRadioactive Decay Iodine Atom Label Tracer Minute Post Injection Receptor Tracer
Unable to display preview. Download preview PDF.
- 1.J. Mertens, and M. Gysemans, CuI+ assisted nucleophilic exchange radiohalogenation: application and mechanistic approach, in: New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and regulatory Control, A.M. Emran, Plenum Press, New York and London (1991).Google Scholar
- 3.J.E. Leysen, W. Gommeren, J. Mertens, W.H.M.L. Luyten, P.J. Pauwels, M. Ewert, and P. Seeburg, Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I]-2′-iodospiperone, Psychopharmac., 110:27–36 (1993).CrossRefGoogle Scholar
- 4.J. Mertens, C. Piron, F. De Geeter, L. Christieans, R. Cantineau, M. Guillaume, and J. Leysen, Evaluation of pure 2′-125I-spiperone as a promising tracer for in vivo D2 receptor study with SPECT, J. NucL Med., 30:926 (1990).Google Scholar
- 5.J. Mertens, “Clustered lipophilic compensation” a new concept in the development of lipophilic radioiodinated and brominated receptor tracers, J. Lab. Comp. Ratiopharm., 30:363 (1991).Google Scholar